Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 12/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.53 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.53 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.53 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.53 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.52 |
| ▸ | PIM1 | P11309 | 1/20 | 0.52 |
| ▸ | CDK8 | P49336 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4023683 | 0.88 | TRPV1 (0.51) | TRPV1ALDH1A1KDM4ESMN1; SMN2HPGD | |
| SCHEMBL8101447 | 0.85 | TRPV1 (0.59) | TRPV1HTTKMT2AMEN1MAPK1 | |
| SCHEMBL5660097 | 0.83 | TRPV1 (0.71) | TRPV1 | |
| SCHEMBL4023786 | 0.81 | TRPV1 (0.64) | TRPV1HTTKMT2AMEN1MAPK1 | |
| SCHEMBL30114438 | 0.81 | TRPV1 (0.64) | TRPV1HTTKMT2AMEN1MAPK1 | |
| SCHEMBL30544195 | 0.80 | KDM4E (0.67) | TRPV1HTTKMT2AMEN1MAPK1 | |
| SCHEMBL2315592 | 0.80 | KDM4E (0.67) | TRPV1HTTKMT2AMEN1MAPK1 | |
| SCHEMBL4023574 | 0.80 | MAPT (0.62) | TRPV1HTTKMT2AMEN1MAPK1 | |
| SCHEMBL6630943 | 0.80 | TRPV1 (0.59) | TRPV1HTTKMT2AMEN1MAPK1 | |
| SCHEMBL31536337 | 0.79 | TRPV1 (0.65) | TRPV1HTTKMT2AMEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247413-B2 | e.g. N-[2-(3-fluorophenyl)ethyl]-N'-isoquinolin-5-ylurea; opioid receptor inhibitor; analgesic, antiinflammatory agent; inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity | ABBOTT LABORATORIES (US) | 2012-08-21 | — | — | US | disclosed |
| US-7795267-B2 | Bicyclic piperazine compound having TGR23 antagonistic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-14 | — | — | US | disclosed |
| EP-1478363-B1 | FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LAB (US) | 2009-01-14 | — | — | EP | disclosed |
| US-20080214524-A1 | FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2008-09-04 | — | — | US | disclosed |
| US-7335678-B2 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1(VR1) receptor | ABBOTT LABORATORIES (US) | 2008-02-26 | — | — | US | disclosed |
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-29 | — | — | US | disclosed |
| US-7074805-B2 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LABORATORIES (US) | 2006-07-11 | — | — | US | disclosed |
| EP-1661898-A1 | BICYCLIC PIPERAZINE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-05-31 | — | — | EP | disclosed |
| EP-1660455-A1 | FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2006-05-31 | — | — | EP | disclosed |
| US-6933311-B2 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LABORATORIES (US) | 2005-08-23 | — | — | US | disclosed |
| US-20050113576-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LABORATORIES | 2005-05-26 | — | — | US | disclosed |
| WO-2005016890-A1 | FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2005-02-24 | — | — | WO | disclosed |
| EP-1478363-A1 | FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | Abbott Laboratories (US) | 2004-11-24 | — | — | EP | disclosed |
| US-20040209884-A1 | Fused azabicycic compounds that inhibit vanilloid receptor subtype 1(VR1) receptor | ABBVIE INC. | 2004-10-21 | — | — | US | disclosed |
| US-20040157849-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2004-08-12 | — | — | US | disclosed |
| WO-2003070247-A1 | FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2003-08-28 | — | — | WO | disclosed |
| US-20030158198-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2003-08-21 | — | — | US | disclosed |
| US-20030158188-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LABORATORIES | 2003-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214524-A1 | FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | TRPV1, TMEM109, VIPR1 | TRPV1 1/4885HTT 4593/4885KMT2A 3095/4885 |
| US-20030158198-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | TRPV1, VIPR1, TMEM109 | TRPV1 1/4885HTT 4583/4885KMT2A 2802/4885 |
| US-20040157849-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | TRPV1, VIPR1, TMEM109 | TRPV1 1/4885HTT 4597/4885KMT2A 2965/4885 |
| US-20040209884-A1 | Fused azabicycic compounds that inhibit vanilloid receptor subtype 1(VR1) receptor | TRPV1, TMEM109, GPR55 | TRPV1 1/4885HTT 4553/4885KMT2A 2105/4885 |
| US-20050113576-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | TRPV1, TMEM109, VIPR1 | TRPV1 1/4885HTT 4593/4885KMT2A 3095/4885 |
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | GPR3, FFAR3, LPAR3 | TRPV1 366/4885HTT 3138/4885KMT2A 922/4885 |
| US-20030158188-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | TRPV1, TMEM109, VIPR1 | TRPV1 1/4885HTT 4593/4885KMT2A 3095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.